Amphetamine oral - Alcobra
Alternative Names: Abuse-Deterrent, Amphetamine Immediate-Release - Alcobra; ADAIRLatest Information Update: 28 Mar 2021
At a glance
- Originator Alcobra
- Developer Alcobra; Capsugel
- Class Amphetamines; Antipsychotics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in Israel (PO, Capsule)
- 06 Jul 2017 Capsugel has been acquired by Lonza
- 30 May 2017 Alcobra announces intention to submit IND to US FDA for Attention-deficit hyperactivity disorder in third quarter of 2017